Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Philip Morris
PM
|
+$245M |
| 2 |
KeyCorp
KEY
|
+$199M |
| 3 |
RTX Corp
RTX
|
+$183M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$170M |
| 5 |
Ralph Lauren
RL
|
+$167M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$245M |
| 2 |
US Bancorp
USB
|
+$216M |
| 3 |
Apple
AAPL
|
+$207M |
| 4 |
Visa
V
|
+$188M |
| 5 |
Bank of America
BAC
|
+$177M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 9.66% |
| 2 | Consumer Discretionary | 8.08% |
| 3 | Energy | 7.71% |
| 4 | Technology | 6.85% |
| 5 | Industrials | 5.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4501
PUT
Badger Meter
BMI
$3.79B
| $233K | ﹤0.01% |
10,000
-6,000
| -38% | -$141K |
|
4502
CALL
Camden Property Trust
CPT
$11.1B
| $233K | ﹤0.01% |
3,800
+3,600
| +1,800% | +$242K |
|
|
NSLR
4503
PUT
Neostellar Capital Corp
NSLR
$278M
| $233K | ﹤0.01% |
24,180
+12,475
| +107% | +$90.7K |
|
|
PGTI
4504
DELISTED
PGT, Inc.
PGTI
| $233K | ﹤0.01% |
23,516
+4,035
| +21% | +$40.7K |
|
|
SRGA
4505
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $233K | ﹤0.01% |
2,075
+951
| +85% | +$108K |
|
|
HK
4506
PUT
DELISTED
Halcon Resources Corporation
HK
| $233K | ﹤0.01% |
306
+162
| +113% | +$148K |
|
4507
PUT
Trimble
TRMB
$13.4B
| $232K | ﹤0.01% |
7,800
-14,700
| -65% | -$402K |
|
|
ZOLT
4508
CALL
DELISTED
ZOLTEK COMPANIES INC
ZOLT
| $232K | ﹤0.01% |
13,900
+800
| +6% | +$11.4K |
|
4509
Madrigal Pharmaceuticals
MDGL
$11.7B
| $231K | ﹤0.01% |
1,045
-278
| -21% | -$59.1K |
|
|
PERY
4510
DELISTED
Perry Ellis International Inc
PERY
| $231K | ﹤0.01% |
12,230
-2,273
| -16% | -$44.5K |
|
|
ZLTQ
4511
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $231K | ﹤0.01% |
25,447
+10,253
| +67% | +$76.1K |
|
|
ENH
4512
PUT
DELISTED
Endurance Specialty Holdings Ltd
ENH
| $231K | ﹤0.01% |
4,300
-4,600
| -52% | -$239K |
|
|
CIM
4513
CALL
Chimera Investment
CIM
$988M
| $230K | ﹤0.01% |
5,040
-1,653
| -25% | -$73.5K |
|
4514
Novartis
NVS
$287B
| $230K | ﹤0.01% |
+3,348
| New | +$222K |
|
|
ATNY
4515
DELISTED
API TECHNOLOGIES CORP. COMMON STOCK
ATNY
| $230K | ﹤0.01% |
78,586
+61,007
| +347% | +$177K |
|
4516
CALL
Carlyle Group
CG
$17.6B
| $229K | ﹤0.01% |
8,900
+800
| +10% | +$21.2K |
|
4517
Forestar Group
FOR
$1.5B
| $229K | ﹤0.01% |
10,632
-38,592
| -78% | -$815K |
|
4518
PUT
Foster
FSTR
$408M
| $229K | ﹤0.01% |
+5,000
| New | +$223K |
|
4519
Harvard Bioscience
HBIO
$30.3M
| $229K | ﹤0.01% |
5,751
+666
| +13% | +$26.2K |
|
4520
PUT
Medifast
MED
$128M
| $229K | ﹤0.01% |
8,500
-4,500
| -35% | -$120K |
|
|
STR
4521
PUT
DELISTED
QUESTAR CORP
STR
| $229K | ﹤0.01% |
10,200
+4,800
| +89% | +$111K |
|
|
CRTX
4522
DELISTED
CORNERSTONE THERAPEUTICS INC
CRTX
| $229K | ﹤0.01% |
24,328
+7,491
| +44% | +$67.5K |
|
|
HK
4523
CALL
DELISTED
Halcon Resources Corporation
HK
| $229K | ﹤0.01% |
299
-166
| -36% | -$151K |
|
4524
Inseego
INSG
$77M
| $228K | ﹤0.01% |
8,740
-9,681
| -53% | -$337K |
|
|
NXGN
4525
CALL
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $228K | ﹤0.01% |
10,500
-5,200
| -33% | -$111K |
|
Similar funds
Ken Griffin's Q3 2013 Portfolio in Review
As of Q3 2013, Ken Griffin held 7,215 positions worth $65.7B, up 13% from $58.1B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Ken Griffin's Q3 2013 filing shows 735 new, 2,740 increased, 3,074 reduced and 505 closed positions. Its largest new stake was ELAN CORP ADS(RP1 ORD4IRISH PN: 6,448,014 shares worth $100M. The largest sale was Pfizer, an estimated $245M.
By sector, the portfolio is most concentrated in Financials at 9.7% of assets, down from 12% a quarter earlier, followed by Consumer Discretionary and Energy.
- Ken Griffin's largest Q3 2013 buy was ELAN CORP ADS(RP1 ORD4IRISH PN: 6,448,014 shares worth $100M.
- Ken Griffin added most to Philip Morris in Q3 2013, an estimated $245M increase.
- Ken Griffin's biggest Q3 2013 reduction was Pfizer, cutting an estimated $245M.
- Ken Griffin fully exited NEWS CORPORATION CL-A in Q3 2013, selling an estimated $166M.
- Ken Griffin's ten largest holdings make up 12% of its $65.7B portfolio in Q3 2013.
- Ken Griffin opened 735 new positions and closed 505 in Q3 2013.
- Ken Griffin's portfolio value rose 13% quarter-over-quarter to $65.7B.
Based on Citadel Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.